$CTOR
Citius Oncology, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$0.541
▲Pre-market+8.18%+$0.041Pre-market
Citius Oncology, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is CTOR up today? It is at $0.541 (+8.18%), and our scanner flagged it 4 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment CTOR spikes, and full due diligence on CTOR — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $CTOR 4 times in the last 30 days. Create a free account to track $CTOR, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on CTOR from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
Likely catalystCitius Oncology's Positive Quality of, from the latest SEC filing. Read it →Across every filing on file, supply equal to 16.3% of the tradeable float is in play - 8% has already been sold, and 8.3% more can still be issued.
Shelf sizes are dollars, so shares are estimated at today's price.
Recent share offering + active shelf on file — the company raised capital and can raise more
7,090,909 new shares
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Dutia Suren G Director | Acquired (grant/award) | +300K 0.3% of company | n/a | 300K | n/a | Sep 19, 25 |
Mcgrath Dennis M Director | Acquired (grant/award) | +300K 0.3% of company | n/a | 300K | n/a | Sep 19, 25 |
Holuka Eugene Myron Director | Acquired (grant/award) | +300K 0.3% of company | n/a | 300K | n/a | Sep 19, 25 |
Bartushak Jaime Officer | Acquired (grant/award) | +825K 0.8% of company | n/a | 825K | n/a | Sep 19, 25 |
Mayersohn Joel David Director | Acquired (grant/award) | +300K 0.3% of company | added 100% | 321K | n/a | Sep 19, 25 |
Webb Carol Director | Acquired (grant/award) | +300K 0.3% of company | n/a | 300K | n/a | Sep 19, 25 |
Holubiak Myron Z Officer | Acquired (grant/award) | +850K 0.8% of company | n/a | 850K | n/a | Sep 19, 25 |
Holubiak Myron Z Officer | Acquired (grant/award) | +100K 0.09% of company | n/a | 100K | n/a | Sep 19, 25 |
Smith Robert Joseph Director | Acquired (grant/award) | +300K 0.3% of company | n/a | 300K | n/a | Sep 19, 25 |
Mazur Leonard L Officer | Acquired (grant/award) | +1.70M 1.6% of company | n/a | 1.70M | n/a | Sep 19, 25 |
Czuczman Myron Officer | Acquired (grant/award) | +825K 0.8% of company | n/a | 825K | n/a | Sep 19, 25 |
Mayersohn Joel David Director | Acquired (grant/award) | +21K 0.02% of company | n/a | 21K | n/a | Jul 28, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on CTOR from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
CTOR last traded at $0.541, up 8.18% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Citius Oncology, Inc. Common Stock (CTOR) is next expected to report earnings on Tuesday, December 22, 2026, about 46 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The CTOR Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged CTOR 4 times in the last 30 days.
CTOR (Citius Oncology, Inc. Common Stock) trades on XNAS, with a market cap of about $53M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge CTOR for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$CTOR discussion
Sign in to ask a question or join the discussion.